JP6954839B2 - アルツハイマー病の診断及び治療のための材料及び方法 - Google Patents

アルツハイマー病の診断及び治療のための材料及び方法 Download PDF

Info

Publication number
JP6954839B2
JP6954839B2 JP2017549301A JP2017549301A JP6954839B2 JP 6954839 B2 JP6954839 B2 JP 6954839B2 JP 2017549301 A JP2017549301 A JP 2017549301A JP 2017549301 A JP2017549301 A JP 2017549301A JP 6954839 B2 JP6954839 B2 JP 6954839B2
Authority
JP
Japan
Prior art keywords
biomarker
sample
biomarkers
subject
biomarker panel
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2017549301A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018510343A5 (enExample
JP2018510343A (ja
Inventor
ヒューゴ ピケ イアン
ヒューゴ ピケ イアン
ルイーズ ラッセル クレア
ルイーズ ラッセル クレア
ワード マルコルム
ワード マルコルム
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Proteome Sciences PLC
Original Assignee
Electrophoretics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Electrophoretics Ltd filed Critical Electrophoretics Ltd
Publication of JP2018510343A publication Critical patent/JP2018510343A/ja
Publication of JP2018510343A5 publication Critical patent/JP2018510343A5/ja
Priority to JP2021102858A priority Critical patent/JP2021177180A/ja
Application granted granted Critical
Publication of JP6954839B2 publication Critical patent/JP6954839B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C49/00—Ketones; Ketenes; Dimeric ketenes; Ketonic chelates
    • C07C49/587—Unsaturated compounds containing a keto groups being part of a ring
    • C07C49/757—Unsaturated compounds containing a keto groups being part of a ring containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y504/00—Intramolecular transferases (5.4)
    • C12Y504/02—Phosphotransferases (phosphomutases) (5.4.2)
    • C12Y504/02002—Phosphoglucomutase (5.4.2.2)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Peptides Or Proteins (AREA)
JP2017549301A 2015-03-17 2016-03-17 アルツハイマー病の診断及び治療のための材料及び方法 Active JP6954839B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021102858A JP2021177180A (ja) 2015-03-17 2021-06-22 アルツハイマー病の診断及び治療のための材料及び方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201504432A GB201504432D0 (en) 2015-03-17 2015-03-17 Materials and methods for diagnosis and treatment of alzheimers disease
GB1504432.4 2015-03-17
PCT/EP2016/055883 WO2016146783A1 (en) 2015-03-17 2016-03-17 Materials and methods for diagnosis and treatment of alzheimer's disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021102858A Division JP2021177180A (ja) 2015-03-17 2021-06-22 アルツハイマー病の診断及び治療のための材料及び方法

Publications (3)

Publication Number Publication Date
JP2018510343A JP2018510343A (ja) 2018-04-12
JP2018510343A5 JP2018510343A5 (enExample) 2019-05-09
JP6954839B2 true JP6954839B2 (ja) 2021-10-27

Family

ID=53016214

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017549301A Active JP6954839B2 (ja) 2015-03-17 2016-03-17 アルツハイマー病の診断及び治療のための材料及び方法
JP2021102858A Pending JP2021177180A (ja) 2015-03-17 2021-06-22 アルツハイマー病の診断及び治療のための材料及び方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021102858A Pending JP2021177180A (ja) 2015-03-17 2021-06-22 アルツハイマー病の診断及び治療のための材料及び方法

Country Status (6)

Country Link
US (1) US10718785B2 (enExample)
EP (1) EP3271728B1 (enExample)
JP (2) JP6954839B2 (enExample)
CA (1) CA2979773A1 (enExample)
GB (1) GB201504432D0 (enExample)
WO (1) WO2016146783A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201509134D0 (en) 2015-05-28 2015-07-15 Electrophoretics Ltd Biomolecules involved in Alzheimer's disease
CA3070446A1 (en) 2017-07-25 2019-01-31 Immutics, Inc. Treating cancer by blocking the interaction of tim-3 and its ligand
KR102034929B1 (ko) * 2017-09-27 2019-10-22 한양대학교 산학협력단 Nckap1 단백질 또는 상기 단백질을 암호화하는 유전자를 포함하는 신경계 퇴행성질환의 예방 또는 치료용 약학적 조성물
KR102063610B1 (ko) * 2018-05-23 2020-01-08 충북대학교 산학협력단 퇴행성 신경질환 진단용 신규한 바이오마커 및 이의 용도
KR102232200B1 (ko) * 2019-03-13 2021-03-25 아주대학교산학협력단 알츠하이머치매 진단 바이오마커
US20220003787A1 (en) * 2018-10-30 2022-01-06 Ajou University Industry-Academic Cooperation Foundation Biomarker proteins for diagnosing alzheimer's dementia and use thereof
KR101992060B1 (ko) * 2018-10-30 2019-06-21 아주대학교산학협력단 알츠하이머치매 진단 체액 바이오마커 후보 단백4종
CN109738653B (zh) * 2019-01-11 2022-04-12 湖南诺琪生物科技有限公司 用于阿尔茨海默症的检测、诊断或风险预测的抗原蛋白组合以及包含其的试剂盒
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CN110261272B (zh) * 2019-07-05 2020-08-18 西南交通大学 基于地理探测和pca对pm2.5浓度分布的关键影响因子筛选方法
CN112336859A (zh) * 2019-08-06 2021-02-09 上海绿谷制药有限公司 通过抑制t细胞摄取氨基酸治疗阿尔茨海默病的方法
KR20220104706A (ko) * 2019-10-28 2022-07-26 에전 알츠하이머병의 침묵 단계를 진단하기 위한 바이오마커 및 이의 용도
KR102313455B1 (ko) * 2020-02-27 2021-10-15 이화여자대학교 산학협력단 알츠하이머병 경도인지장애의 진단 또는 알츠하이머병 치매로의 진행 위험성 예측 방법
EP4157338A4 (en) 2020-05-26 2024-11-13 TrueBinding, Inc. METHOD FOR TREATING INFLAMMATORY DISEASES BY GALECTIN-3 BLOCKING
CN112695084A (zh) * 2021-02-08 2021-04-23 山东大学第二医院 诊断阿尔茨海默病和阿尔茨海默病进展的生物标志物及应用
GB202102399D0 (en) * 2021-02-19 2021-04-07 Univ Manchester Methods of determining alzheimer's disease
US20250270618A1 (en) * 2021-03-08 2025-08-28 The Children's Medical Center Corporation Methods for diagnosis and treatment of alzheimer's disease
US20230144446A1 (en) * 2021-07-23 2023-05-11 Cassava Sciences, Inc. Blood-based diagnostic assays for alzheimer's disease
WO2023235871A2 (en) * 2022-06-03 2023-12-07 Seer, Inc. Systems, compositions, and methods relating to neurodegenerative diseases
WO2024073067A2 (en) * 2022-09-30 2024-04-04 Mayo Foundation For Medical Education And Research Assessing and treating tremor

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
JPWO2004001865A1 (ja) 2002-06-19 2005-10-27 株式会社東芝 熱電素子とそれを用いた電子部品モジュールおよび携帯用電子機器
WO2005020784A2 (en) 2003-05-23 2005-03-10 Mount Sinai School Of Medicine Of New York University Surrogate cell gene expression signatures for evaluating the physical state of a subject
WO2005019825A2 (en) * 2003-08-20 2005-03-03 Genova Ltd. Secreted polypeptide species and use thereof
US7794948B2 (en) * 2003-11-07 2010-09-14 Vermilllion, Inc. Biomarkers for alzheimer's disease
WO2006110621A2 (en) * 2005-04-11 2006-10-19 Cornell Research Foundation, Inc. Multiplexed biomarkers for monitoring the alzheimer's disease state of a subject
ES2453106T3 (es) * 2009-01-26 2014-04-04 Electrophoretics Limited Métodos de diagnóstico y pronóstico en relación con la enfermedad de Alzheimer
WO2010111587A1 (en) 2009-03-26 2010-09-30 Trustees Of The University Of Pennsylvania Modulators of tdp-43 mediated toxicity
WO2011005893A2 (en) * 2009-07-07 2011-01-13 Abbott Laboratories Biomarkers and methods for detecting alzheimer's disease
EP2553466A4 (en) 2010-04-01 2013-10-16 Banyan Biomarkers Inc MARKERS AND ASSAYS FOR DETECTING NEUROTOXICITY
WO2013086429A2 (en) * 2011-12-09 2013-06-13 Veracyte, Inc. Methods and compositions for classification of samples
GB2511525A (en) * 2013-03-05 2014-09-10 Randox Teoranta Methods and Compositions for the Diagnosis of Alzheimer's Disease
GB201310203D0 (en) * 2013-06-07 2013-07-24 Electrophoretics Ltd Materials and methods relating to Alzheimer's disease
GB201322094D0 (en) * 2013-12-13 2014-01-29 Electrophoretics Ltd Methods and compositions relating to alzheimers disease

Also Published As

Publication number Publication date
US10718785B2 (en) 2020-07-21
WO2016146783A1 (en) 2016-09-22
JP2018510343A (ja) 2018-04-12
US20180067133A1 (en) 2018-03-08
JP2021177180A (ja) 2021-11-11
GB201504432D0 (en) 2015-04-29
CA2979773A1 (en) 2016-09-22
EP3271728B1 (en) 2024-02-28
EP3271728A1 (en) 2018-01-24

Similar Documents

Publication Publication Date Title
JP6954839B2 (ja) アルツハイマー病の診断及び治療のための材料及び方法
Roche et al. Clinical proteomics of the cerebrospinal fluid: towards the discovery of new biomarkers
AU2005288689B2 (en) Methods and compositions relating to Alzheimer's disease
JP5479379B2 (ja) アルツハイマー病のためのバイオマーカー
EP2569446B1 (en) Diagnostic markers for neuropsychiatric diseasen
JP7241104B2 (ja) アルツハイマー病に関係する生体分子
Zhang et al. Proteomic biomarker discovery in cerebrospinal fluid for neurodegenerative diseases
US9738709B2 (en) Methylated peptides derived from tau protein and their antibodies for diagnosis and therapy of alzheimer's disease
DK2389587T3 (en) Diagnostic and prognostic methods related Alzheimer's Disease
Zhang et al. Proteomics of human neurodegenerative diseases
WO2015020523A1 (en) Biomarkers for early diagnosis of alzheimer's disease
JP7457300B2 (ja) 神経変性疾患の診断用ペプチドマーカー
WO2006108051A2 (en) Compositions and methods relating to alzheimer's disease
WO2005116659A2 (en) Compositions and methods relating to alzheimer’s disease
AU2011253636B2 (en) Methods and compositions relating to alzheimer's disease
Lindström Quantifying soluble isoforms of amyloid precursor protein in cerebrospinal fluid with a SRM-MS based assay─ method development

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171214

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190315

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190315

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191114

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200114

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200708

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201030

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210224

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210622

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20210622

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20210701

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20210706

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210921

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210930

R150 Certificate of patent or registration of utility model

Ref document number: 6954839

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250